These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 18597186)
1. The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor. Ceraudo E; Tan YV; Nicole P; Couvineau A; Laburthe M J Mol Neurosci; 2008 Nov; 36(1-3):245-8. PubMed ID: 18597186 [TBL] [Abstract][Full Text] [Related]
2. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor. Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162 [TBL] [Abstract][Full Text] [Related]
3. The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics. Ceraudo E; Murail S; Tan YV; Lacapère JJ; Neumann JM; Couvineau A; Laburthe M Mol Endocrinol; 2008 Jan; 22(1):147-55. PubMed ID: 17885205 [TBL] [Abstract][Full Text] [Related]
4. Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP. Tan YV; Couvineau A; Laburthe M J Biol Chem; 2004 Sep; 279(37):38889-94. PubMed ID: 15247290 [TBL] [Abstract][Full Text] [Related]
5. Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction. Ceraudo E; Hierso R; Tan YV; Murail S; Rouyer-Fessard C; Nicole P; Robert JC; Jamin N; Neumann JM; Robberecht P; Laburthe M; Couvineau A FASEB J; 2012 May; 26(5):2060-71. PubMed ID: 22291440 [TBL] [Abstract][Full Text] [Related]
6. VPAC1 receptor binding site: contribution of photoaffinity labeling approach. Couvineau A; Ceraudo E; Tan YV; Laburthe M Neuropeptides; 2010 Apr; 44(2):127-32. PubMed ID: 20031208 [TBL] [Abstract][Full Text] [Related]
7. Peptide agonist docking in the N-terminal ectodomain of a class II G protein-coupled receptor, the VPAC1 receptor. Photoaffinity, NMR, and molecular modeling. Tan YV; Couvineau A; Murail S; Ceraudo E; Neumann JM; Lacapère JJ; Laburthe M J Biol Chem; 2006 May; 281(18):12792-8. PubMed ID: 16520374 [TBL] [Abstract][Full Text] [Related]
8. Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor. Tan YV; Couvineau A; Van Rampelbergh J; Laburthe M J Biol Chem; 2003 Sep; 278(38):36531-6. PubMed ID: 12807902 [TBL] [Abstract][Full Text] [Related]
9. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling. Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167 [TBL] [Abstract][Full Text] [Related]
10. Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor. Couvineau A; Robert JC; Ramdani T; Lacapère JJ; Rouyer-Fessard C; Laburthe M J Mol Neurosci; 2008 Nov; 36(1-3):249-53. PubMed ID: 18592417 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the new photoaffinity probe (Bz2-K24)-VIP. Tan YV; Couvineau A; Lacapere JJ; Laburthe M Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228 [TBL] [Abstract][Full Text] [Related]
13. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Couvineau A; Laburthe M Br J Pharmacol; 2012 May; 166(1):42-50. PubMed ID: 21951273 [TBL] [Abstract][Full Text] [Related]
14. Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs. Couvineau A; Tan YV; Ceraudo E; Laburthe M Methods Enzymol; 2013; 520():219-37. PubMed ID: 23332702 [TBL] [Abstract][Full Text] [Related]
15. Expression and localization of VPAC1, the major receptor of vasoactive intestinal peptide along the length of the intestine. Jayawardena D; Guzman G; Gill RK; Alrefai WA; Onyuksel H; Dudeja PK Am J Physiol Gastrointest Liver Physiol; 2017 Jul; 313(1):G16-G25. PubMed ID: 28385693 [TBL] [Abstract][Full Text] [Related]
16. Human VPAC1 receptor selectivity filter. Identification of a critical domain for restricting secretin binding. Du K; Couvineau A; Rouyer-Fessard C; Nicole P; Laburthe M J Biol Chem; 2002 Oct; 277(40):37016-22. PubMed ID: 12133828 [TBL] [Abstract][Full Text] [Related]
17. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor. Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688 [TBL] [Abstract][Full Text] [Related]
18. The VPAC1 receptor: structure and function of a class B GPCR prototype. Couvineau A; Ceraudo E; Tan YV; Nicole P; Laburthe M Front Endocrinol (Lausanne); 2012; 3():139. PubMed ID: 23162538 [TBL] [Abstract][Full Text] [Related]
19. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor. Couvineau A; Rouyer-Fessard C; Laburthe M Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910 [TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors. Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]